Evidence supporting the use of: EPA (eicosapentaenoic acid)
For the health condition: Autism

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Eicosapentaenoic acid (EPA), an omega-3 fatty acid found primarily in fish oil, has been explored as a potential supplement for individuals with autism spectrum disorder (ASD). The interest in EPA stems from its anti-inflammatory properties and its role in supporting brain health and function. Some studies have reported that children with autism may have altered fatty acid metabolism or lower levels of omega-3 fatty acids, which has led researchers to investigate whether supplementation could improve core symptoms or associated behaviors such as hyperactivity, irritability, or communication difficulties.

However, the scientific evidence supporting EPA’s efficacy in treating autism is limited and mixed. A few small randomized controlled trials (RCTs) and open-label studies have shown modest improvements in some behavioral symptoms with omega-3 supplementation (often as a combination of EPA and DHA), but other trials have failed to demonstrate significant benefits over placebo. Systematic reviews and meta-analyses published in recent years (such as those in Journal of Autism and Developmental Disorders and Cochrane Reviews) conclude that, while omega-3s are generally safe, the overall quality of evidence is low, and the effect sizes are small or non-significant.

In summary, EPA is being used based on plausible biological mechanisms and some preliminary clinical findings, but robust scientific validation is lacking. More large-scale, well-designed studies are needed to determine whether EPA supplementation provides meaningful benefits for people with autism.

More about EPA (eicosapentaenoic acid)
More about Autism